46 results on '"Orsini-Piocelle, Frédérique"'
Search Results
2. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
3. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
4. A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
5. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
6. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features
7. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
8. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified
9. RAS/RAF landscape in monoclonal plasma cell conditions
10. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
11. Increased risk of infection reporting with anti‐BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study
12. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
13. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
14. MM-491 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study
15. Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study
16. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones
17. Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients
18. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
19. A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
20. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
21. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA):an open-label, randomised, phase 3 trial
22. Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03
23. Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05
24. Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies
25. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
26. Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients
27. A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
28. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
29. OAB-016: High risk subclones detected at relapse are present from diagnosis in small subclones and impact the prognosis
30. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
31. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma
32. Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
33. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
34. miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study
35. Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study.
36. Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)
37. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
38. Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial
39. Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association
40. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial
41. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
42. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
43. Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.
44. [Nurturing and growing a community of department heads: Act 2 in haematology].
45. Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.
46. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.